NKG2D配体作为治疗靶点。
NKG2D ligands as therapeutic targets.
作者信息
Spear Paul, Wu Ming-Ru, Sentman Marie-Louise, Sentman Charles L
机构信息
Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA.
出版信息
Cancer Immun. 2013 May 1;13:8. Print 2013.
Abstract
The Natural Killer Group 2D (NKG2D) receptor plays an important role in protecting the host from infections and cancer. By recognizing ligands induced on infected or tumor cells, NKG2D modulates lymphocyte activation and promotes immunity to eliminate ligand-expressing cells. Because these ligands are not widely expressed on healthy adult tissue, NKG2D ligands may present a useful target for immunotherapeutic approaches in cancer. Novel therapies targeting NKG2D ligands for the treatment of cancer have shown preclinical success and are poised to enter into clinical trials. In this review, the NKG2D receptor and its ligands are discussed in the context of cancer, infection, and autoimmunity. In addition, therapies targeting NKG2D ligands in cancer are also reviewed.
摘要
自然杀伤细胞2D（NKG2D）受体在保护宿主免受感染和癌症侵害方面发挥着重要作用。通过识别感染或肿瘤细胞上诱导产生的配体，NKG2D调节淋巴细胞活化并促进免疫反应以清除表达配体的细胞。由于这些配体在健康成人组织中并非广泛表达，NKG2D配体可能成为癌症免疫治疗方法的有用靶点。针对NKG2D配体治疗癌症的新型疗法已在临床前研究中取得成功，并有望进入临床试验。在本综述中，将在癌症、感染和自身免疫的背景下讨论NKG2D受体及其配体。此外，还将综述针对癌症中NKG2D配体的疗法。
相似文献
1
NKG2D ligands as therapeutic targets.
Cancer Immun. 2013 May 1;13:8. Print 2013.
2
NKG2D signaling in cancer immunosurveillance.
Int J Cancer. 2015 Apr 15;136(8):1741-50. doi: 10.1002/ijc.28775. Epub 2014 Mar 3.
3
Natural killer group 2D receptor and its ligands in cancer immune escape.
Mol Cancer. 2019 Feb 27;18(1):29. doi: 10.1186/s12943-019-0956-8.
4
NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment.
Front Immunol. 2019 Mar 29;10:661. doi: 10.3389/fimmu.2019.00661. eCollection 2019.
5
Cancer immunotherapy using NKG2D and DNAM-1 systems.
Anticancer Res. 2012 Jun;32(6):2241-7.
6
Murine NKG2D ligands: "double, double toil and trouble".
Mol Immunol. 2009 Mar;46(6):1011-9. doi: 10.1016/j.molimm.2008.09.035. Epub 2008 Dec 10.
7
Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection.
Science. 2015 Apr 3;348(6230):136-9. doi: 10.1126/science.1258867. Epub 2015 Mar 5.
8
Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies.
Front Immunol. 2024 Aug 29;15:1457887. doi: 10.3389/fimmu.2024.1457887. eCollection 2024.
9
NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.
Front Immunol. 2018 Sep 11;9:2040. doi: 10.3389/fimmu.2018.02040. eCollection 2018.
10
Advances in NKG2D ligand recognition and responses by NK cells.
Immunol Cell Biol. 2014 Mar;92(3):230-6. doi: 10.1038/icb.2013.111. Epub 2014 Jan 21.
引用本文的文献
1
Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances.
J Exp Clin Cancer Res. 2025 Aug 23;44(1):251. doi: 10.1186/s13046-025-03503-7.
2
Designs of NKG2D-based immunotherapeutics for cancer.
Front Immunol. 2025 Jun 19;16:1557644. doi: 10.3389/fimmu.2025.1557644. eCollection 2025.
3
Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL.
Front Immunol. 2025 May 9;16:1557405. doi: 10.3389/fimmu.2025.1557405. eCollection 2025.
4
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors.
Front Immunol. 2025 Jan 6;15:1489827. doi: 10.3389/fimmu.2024.1489827. eCollection 2024.
5
Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy.
Clin Transl Med. 2024 Nov;14(11):e70046. doi: 10.1002/ctm2.70046.
6
CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside.
Mol Cancer. 2024 Oct 23;23(1):237. doi: 10.1186/s12943-024-02151-3.
7
Advances on immunotherapy for osteosarcoma.
Mol Cancer. 2024 Sep 9;23(1):192. doi: 10.1186/s12943-024-02105-9.
8
Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome.
Pharm Res. 2024 Sep;41(9):1757-1773. doi: 10.1007/s11095-024-03761-8. Epub 2024 Aug 26.
9
CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma.
Front Immunol. 2024 Jun 24;15:1383136. doi: 10.3389/fimmu.2024.1383136. eCollection 2024.
10
CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?
Biomedicines. 2024 May 28;12(6):1194. doi: 10.3390/biomedicines12061194.
本文引用的文献
1
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.
J Clin Invest. 2012 Oct;122(10):3718-30. doi: 10.1172/JCI61931. Epub 2012 Sep 4.
2
Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis.
Clin Sarcoma Res. 2012 Feb 8;2(1):8. doi: 10.1186/2045-3329-2-8.
3
Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.
J Immunol. 2012 Jun 15;188(12):6389-98. doi: 10.4049/jimmunol.1103019. Epub 2012 May 14.
4
Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.
PLoS One. 2012;7(2):e31210. doi: 10.1371/journal.pone.0031210. Epub 2012 Feb 15.
5
Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.
Cell. 2012 Feb 17;148(4):739-51. doi: 10.1016/j.cell.2011.12.031.
6
HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
J Immunol. 2012 Mar 1;188(5):2136-45. doi: 10.4049/jimmunol.1102237. Epub 2012 Feb 1.
7
Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.
Cancer Res. 2012 Jan 15;72(2):460-71. doi: 10.1158/0008-5472.CAN-11-1977. Epub 2011 Nov 18.
8
Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.
Cancer Res. 2011 Nov 1;71(21):6621-32. doi: 10.1158/0008-5472.CAN-11-0792. Epub 2011 Sep 21.
9
Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression.
PLoS One. 2011;6(8):e23023. doi: 10.1371/journal.pone.0023023. Epub 2011 Aug 9.
10
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.
J Clin Invest. 2011 Sep;121(9):3609-22. doi: 10.1172/JCI45816. Epub 2011 Aug 15.
Zotero 插件